Adding Ublituximab to Ibrutinib Improves ORR in High-risk CLL

Share this content:
Adding ublituximab to ibrutinib significantly improved overall response rate vs ibrutinib alone in patients with high-risk CLL.
Adding ublituximab to ibrutinib significantly improved overall response rate vs ibrutinib alone in patients with high-risk CLL.

Adding ublituximab (TG-1101) to ibrutinib significantly improved the proportion of patients with high-risk chronic lymphocytic leukemia (CLL) achieving an objective response compared with ibrutinib alone, according to a press release by TG Therapeutics.1

Preliminary results of the multicenter, open-label, phase 3 GENUINE trial (ClinicalTrials.gov Identifier: NCT02301156) demonstrated a significant improvement in overall response rate with ublituximab plus ibrutinib compared with ibrutinib alone in both the intent-to-treat population (P = .001) and the treated population (80% vs 47%; P < .001).

In addition to overall response rate, the investigators observed advantages with the combination in radiographic complete response rate, progression-free survival, and time to response.

The combination was well-tolerated and the safety profile was consistent with findings from a previously reported phase 2 study. The most common adverse events among patients treated with ublituximab plus ibrutinib in the phase 2 trial were infusion-related reaction, diarrhea, fatigue, cough, rash, and nausea.

The study enrolled 126 previously treated patients from the United States and Ireland with high-risk CLL, defined as having 1 or more of the following: 17p deletion, 11q deletion, or p53 mutation. Participants were randomly assigned 1:1 to receive intravenous ublituximab, a highly potent next generation glycoengineered anti-CD20 monoclonal antibody, plus ibrutinib or ibrutinib monotherapy.

RELATED: CLL: Long-term Outcomes After Ibrutinib Discontinuation

The investigators plan to submit detailed findings from the GENUINE study for presentation at an upcoming medical congress.

Reference

  1. TG Therapeutics announces positive topline data from phase 3 GENUINE study of TG-1101 in combination with ibrutinib in patients with high risk chronic lymphocytic leukemia (CLL) [news release]. New York, NY: TG Therapeutics; March 6, 2017. http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=1015939. Accessed March 7, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters